Early Access — free while we kick the tires
EdgarHawk

VanHimbergen Robert M

EVP and CFO

Officer
2 filings analyzed · 2 companies · Latest 2025-12-15

Companies

Company Buys Sells Direction
Elanco Animal Health Inc ELAN 1 0 Net buying
Hillenbrand, Inc. HI 1 0 Net buying

Activity

December 2025
medium
Buy
6,950 shares
$150,426
Significance 6/10

CFO Robert VanHimbergen buys 6,950 shares of ELAN at $21.64; cluster of 3 other insiders bought within 14 days; stock down 7.4% from 52-week high

CFO VanHimbergen acquired 6,950 shares at $21.64, increasing his position from 117,283 to 124,233 shares. The transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated internal confidence amid broader context. However, context is mixed: ELAN trades at P/E of 310.00 with negative net income of $-34,000,000, annual revenue growth of only +0.5%, and the stock sits 7.4% below its 52-week high. VanHimbergen's cross-ticker track record shows an underwhelming 25.00% win rate over 90 days with average 90d return of -4.9%, meaning his past open-market buys have historically faced headwinds. The purchase near current price of $21.70 occurs in a fundamentally challenged environment.

February 2025
2025-02-10 Hillenbrand, Inc. HI
high
Buy
2,000 shares
$65,698
Significance 6/10

CFO VanHimbergen bought 2,000 shares at $32.85; cluster of 3 other insiders also bought in past 14 days; stock -33.7% from 52-week high.

Robert M VanHimbergen, Sr. VP and CFO of Hillenbrand, Inc., purchased 2,000 shares at $32.85 on 2025-02-10, increasing his holdings to 59,595 shares. This transaction is notable because it coincides with a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated management interest at the current valuation. The stock is currently trading at $33.33, down 33.7% from its 52-week high of $50.29, though it has recovered +8.3% over the past 30 days. VanHimbergen's prior buy at this ticker on 2023-12-07 delivered a strong 90-day return of +20.7%, but his next two purchases (2024-02-09 and 2024-05-03) each saw 90-day declines of -1.2% and -2.3% respectively. The company reported annual revenue growth of +12.6% and $706.9M in latest quarterly revenue, but remains unprofitable on a full-year basis, which may explain management's interest in accumulating equity at a depressed price level relative to recent highs.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access